Trials / Completed
CompletedNCT05895500
Evaluate the Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Antagonists in Patients With Dry Eye Disease and Asthenopia
An Investigator-Initiated Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of CGRP Antagonists in Patients With Dry Eye Disease and Asthenopia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 103 (actual)
- Sponsor
- Nvision Laser Eye Centers · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Safety and Efficacy of Medications for Migraine in Patients with Dry Eye Disease or Asthenopia
Detailed description
An Investigator-Initiated Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Medications for Migraine in Patients with Dry Eye Disease or Asthenopia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Injection for SC administration (120mg/syringe) | Injection |
| DRUG | Tablet (50mg/tablet), oral | Tablet |
Timeline
- Start date
- 2023-05-10
- Primary completion
- 2023-11-09
- Completion
- 2023-11-09
- First posted
- 2023-06-08
- Last updated
- 2024-06-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05895500. Inclusion in this directory is not an endorsement.